According to filings with the U.S. Securities and Exchange Commission, Inhibrx is raising $200,000,633.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mark Lappe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inhibrx
At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet specific needs of unique biological targets. Our sdAb-based therapeutic candidates have been designed to interface with the biology of each target antigen, and can be readily manufactured at high yields with established processes. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions, including the ability to:- effectively cluster receptors with precisely defined valency;- simultaneously engage multiple antigens or epitopes;- combine synergistic functions in a single molecule; and- restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.

To learn more about Inhibrx, visit http://inhibrx.com/

Contact:
Mark Lappe, Chief Executive Officer
858-795-4220
https://www.linkedin.com/in/mark-lappe-91a44615/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.